0001144204-11-058566.txt : 20111020 0001144204-11-058566.hdr.sgml : 20111020 20111020095929 ACCESSION NUMBER: 0001144204-11-058566 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20110921 FILED AS OF DATE: 20111020 DATE AS OF CHANGE: 20111020 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 3SBio Inc. CENTRAL INDEX KEY: 0001383790 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33295 FILM NUMBER: 111149321 BUSINESS ADDRESS: STREET 1: NO.3 A1, ROAD 10 SHENYANG STREET 2: ECONOMY & TECHNOLOGY DEVELOPMENT ZONE CITY: SHENYANG STATE: F4 ZIP: 110027 BUSINESS PHONE: 86-24-2581-1820 MAIL ADDRESS: STREET 1: NO.3 A1, ROAD 10 SHENYANG STREET 2: ECONOMY & TECHNOLOGY DEVELOPMENT ZONE CITY: SHENYANG STATE: F4 ZIP: 110027 6-K 1 v237654_6k.htm FORM 6-K Unassociated Document
 
 
FORM 6-K
 
 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
 
 

REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of September 2011
 
Commission File Number: 000-33295
 
 

3SBIO INC.
(Translation of registrant’s name into English)
 
 

No. 3 A1, Road 10
Shenyang Economy & Technology Development Zone
Shenyang 110027
People’s Republic of China
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
Form 20-F  x            Form 40-F  ¨
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):             
 
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes  ¨            No  x
 
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-    N/A
 
 
 

 
 
3SBio Inc. is furnishing under the cover of Form 6-K:
 
Exhibit 99.1 Press release, dated  September 21, 2011, regarding that 3SBio Inc. announces results of 2011 annual general meeting.
 

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
 
 
By:
/s/ Dr. Jing Lou  
       
       
  Name:  Dr. Jing Lou  
  Title:  Chief Executive Officer  
       

Date: September 29, 2011
 

 

 
EXHIBIT INDEX
 
 
Exhibit No.
 
 
Description
     
Exhibit 99.1
 
Press release, dated  September 21, 2011, regarding that 3SBio Inc. announces results of 2011 annual general meeting.
 
 
 
 

 
 
EX-99.1 2 v237654_ex99-1.htm EXHIBIT 99.1 Unassociated Document
 
Exhibit 99.1
 
 
FOR IMMEDIATE RELEASE

 
3SBIO INC. ANNOUNCES RESULTS OF 2011 ANNUAL GENERAL MEETING
 
SHENYANG, China, September 21, 2011-- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the results of shareholder votes at its Annual General Meeting of shareholders held on September 20, 2011.
 
At the meeting, the Company's shareholders re-elected Mr. Lawrence S. Wizel and Mr. Mingde Yu to serve as members of the Board of Directors, until the expiration of their term.
 
The Company's shareholders also ratified the appointment of Ernst & Young Hua Ming to serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2011.
 
About 3SBio Inc.
 
3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 700 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol “SSRX”. Please see www.3SBio.com for more information
 
Investor Contacts
 
Bo Tan
Tom Folinsbee
Chief Financial Officer
Director of Investor Relations
3SBio Inc.
3SBio Inc.
Tel: + 86 24 2581-1820
Tel: + 852 8191-6991
ir@3SBio.com
ir@3SBio.com
 
 
< END>